Meeting
2015 ASCO Annual Meeting
The use of adjuvant treatment in stage I endometrioid endometrial cancer in the National Cancer Database (NCDB).
Authors
Angela Jain
Fox Chase Cancer Ctr, Havertown, PA
Angela Jain , Elizabeth Handorf , Gina Mantia-Smaldone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5599)
DOI
10.1200/jco.2015.33.15_suppl.5599
Abstract #
5599
Poster Bd #
157
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial versus an external control arm from the Flatiron Health database.
First Author: Robert L. Coleman
Poster
2023 ASCO Annual Meeting
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
First Author: Florence Joly
Poster
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
First Author: Alessandro Santin
First Author: B.J. Rimel